Our prior work in both triple-negative and HER2+ breast cancer suggest heterogeneity in adaptive reprogramming makes targeting the response challenging; in this study we have found in HER2+ breast tumors that targeting underlying epigenetic mechanisms of reprogramming may be feasible and circumvent variability in expressed adaptations. This evidence concerns the gene ERBB2 and breast cancer.